common
variabl
immunodefici
cvid
common
symptomat
primari
immunodefici
character
profound
antibodi
diagnosi
repres
heterogen
group
genet
etiolog
character
share
phenotyp
reduc
serum
level
igg
low
iga
andor
igm
impair
antibodi
respons
vaccin
number
typic
present
low
normal
level
wherea
number
may
decreas
cvid
believ
result
absenc
matur
memori
b
cell
plasma
cell
due
varieti
potenti
mechan
poorli
understood
mani
patient
cvid
experi
heighten
suscept
infect
autoimmun
inflammatori
complic
eg
autoimmun
cytopenia
enteropathi
lung
diseas
notabl
patient
cvid
lowest
level
memori
b
cell
report
greatest
risk
antibodi
defici
promin
featur
cvid
ig
replac
therapi
standard
care
although
treatment
seem
alter
cours
autoimmun
inflammatori
complic
mani
common
infect
patient
cvid
involv
respiratori
tract
report
one
larg
studi
bronchiti
sinus
frequent
manifest
pneumonia
also
occur
half
recurr
sinopulmonari
infect
patient
cvid
typic
caus
encapsul
organ
streptococcu
pneumonia
haemophilu
influenza
viral
pathogen
rhinoviru
coronaviru
adenoviru
influenza
pulmonari
infect
sever
recurr
patient
may
develop
irrevers
lung
damag
bronchiectasi
occur
mycoplasma
ureaplasma
recogn
caus
infect
patient
may
involv
atyp
locat
joint
notabl
ig
replac
therapi
shown
reduc
incid
pneumonia
onset
bronchiectasi
sever
respiratori
tract
infect
cvid
although
role
limit
sinus
less
cvid
patient
bronchiectasi
chronic
pulmonari
symptom
recurr
infect
may
persist
despit
standard
ig
patient
may
benefit
aim
higher
igg
trough
level
decreas
pneumonia
observ
everi
mgdl
increment
increas
igg
trough
level
higher
igg
trough
level
achiev
either
frequent
ig
replac
dose
administr
higher
dose
per
treatment
addit
prophylact
antibiot
consid
patient
continu
infect
despit
ig
replac
therapi
gener
azithromycin
amoxicillin
tabl
acut
chronic
diarrhea
remain
common
gastrointestin
gi
symptom
patient
giardia
lamblia
common
caus
infecti
diarrhea
patient
cvid
erad
may
difficult
lead
chronic
diarrhea
metabol
complic
malabsorpt
recent
infect
noroviru
report
import
enter
infect
patient
cvid
also
associ
chronic
infect
caus
malabsorpt
sever
patient
may
benefit
antivir
therapi
clear
noroviru
patient
also
predispos
gi
infect
campylobact
jejuni
salmonella
speci
cytomegaloviru
cmv
surprisingli
despit
frequent
cours
antibiot
patient
cvid
appear
greater
risk
gener
popul
infect
due
clostridium
thu
addit
infect
sinopulmonari
tract
gi
pathogen
major
concern
cvid
howev
impact
ig
replac
therapi
gi
complic
clear
may
overshadow
role
iga
mucos
surfac
replenish
treatment
agammaglobulinemia
xla
primari
immunodefici
caus
mutat
gene
bruton
tyrosin
kinas
btk
result
profound
lymphopenia
agammaglobulinemia
xla
also
associ
sever
transient
neutropenia
impair
receptor
tlr
ig
replac
therapi
standard
care
xla
mani
provid
also
includ
prophylact
antibiot
manag
patient
tabl
cvid
ig
replac
may
dose
achiev
higher
trough
igg
level
concern
bronchiectasi
chronic
sinus
nonbacteri
similar
patient
cvid
patient
xla
typic
recurr
bacteri
infect
upper
lower
respiratori
tract
mycoplasma
ureaplasma
infect
caus
pneumonia
well
destruct
septic
patient
xla
also
suscept
infect
campylobact
helicobact
respons
cellul
ulcer
lower
extrem
bacteremia
osteomyel
septic
arthriti
addit
gi
set
transient
neutropenia
patient
xla
present
pseudomona
staphylococcu
prophylact
antibiot
may
particularli
use
prevent
infect
bout
neutropenia
final
like
patient
cvid
patient
xla
present
enteropathi
secondari
giardia
campylobact
addit
bacteri
pathogen
parasit
patient
xla
increas
suscept
enteroviru
infect
polioviru
coxsackieviru
echoviru
becom
chronic
enteroviru
infect
progress
meningoenceph
fatal
dissemin
fortun
complic
decreas
sinc
ig
replac
therapi
becom
syndrom
collect
name
heterogen
group
disord
unit
defect
antibodi
isotyp
class
switch
somat
common
caus
mutat
gene
encod
ligand
thu
often
call
syndrom
xhigm
common
autosom
recess
form
condit
result
genet
defici
cytidin
deaminas
aid
wherea
mutat
gene
encod
uracil
ung
rare
immunodefici
syndrom
elev
serum
igm
without
complet
impair
antibodi
isotyp
switch
includ
hypohidrot
ectoderm
dysplasia
immunodefici
due
mutat
nuclear
factor
activ
b
cell
essenti
modul
nemo
mutat
delta
subunit
kinas
patient
cvid
otherwis
genet
etiolog
consist
syndrom
infect
upper
lower
respiratori
tract
ear
skin
soft
tissu
gi
tract
commonli
report
infecti
manifest
patient
note
addit
common
bacteri
pathogen
includ
pneumonia
pseudomona
aeruginosa
pneumocysti
jiroveci
pjp
pneumonia
common
patient
xhigm
fact
pjp
pneumonia
present
manifest
syndrom
almost
half
diagnos
associ
pjp
pneumonia
like
due
role
effector
function
includ
activ
macrophag
immun
cell
kill
intracellular
pathogen
thu
patient
effect
combin
immunodefici
fact
mutat
ligand
nemo
appear
highli
associ
sever
infect
opportunist
infect
like
due
impair
macrophag
activ
effector
cryptosporidium
also
frequent
report
patient
higm
infect
contribut
high
rate
scleros
cholang
hepatobiliari
patient
appear
increas
risk
parvoviru
candida
infect
patient
nemo
defect
may
especi
prone
invas
bacteri
infect
abscess
mening
arthriti
osteomyel
sepsi
well
chronic
infect
includ
mycobacterium
avium
patient
higm
demonstr
higher
mortal
compar
patient
pid
diseas
due
infecti
complic
complic
hepatobiliari
patient
treat
combin
ig
replac
pjp
prophylaxi
lifestyl
modif
clean
drink
practic
minim
risk
exposur
cryptosporidium
patient
nemo
defect
gener
prescrib
antibiot
tabl
hematopoiet
stem
cell
transplant
hsct
consid
definit
hsct
appear
superior
outcom
perform
earlier
age
onset
sever
infect
result
damag
specif
antibodi
defici
sad
character
normal
serum
concentr
igg
poor
igg
antibodi
respons
specif
pathogen
commonli
polysaccharid
antigen
per
diagnost
guidelin
patient
must
older
year
age
howev
clear
antibodi
respons
carbohydr
antigen
delay
well
adolesc
caus
difficult
diagnosi
establish
patient
sad
usual
present
recurr
bacteri
sinopulmonari
infect
otiti
media
sinus
pneumonia
due
encapsul
bacteria
system
invas
opportunist
infect
warrant
frequenc
sever
infect
patient
sad
may
manag
prophylact
antibiot
ig
replac
therapi
good
syndrom
first
describ
dr
robert
good
rare
immunodefici
character
find
thymoma
associ
estim
patient
thymoma
half
case
find
thymoma
predat
find
hypogammaglobulinemia
patient
may
identifi
good
syndrom
delay
month
case
thymoma
hypogammaglobulinemia
diagnos
concurr
averag
age
first
present
year
appear
sex
addit
hypogammaglobulinemia
key
laboratori
find
includ
profound
lymphopenia
impair
immun
lymphopenia
invert
ratio
neutropenia
clinic
cours
mark
frequent
sever
invas
bacteri
viral
fungal
opportunist
infect
describ
note
pattern
infect
seen
patient
cvid
may
profound
hypogammaglobulinemia
patient
hiv
demonstr
sever
lymphopenia
regard
bacteri
infect
highli
report
pneumonia
upper
respiratori
infect
gi
infect
pathogen
frequent
associ
patient
upper
lower
respiratori
infect
includ
h
influenza
type
b
p
aeruginosa
pneumonia
klebsiella
common
gi
pathogen
includ
salmonella
c
jejuni
patient
good
syndrom
appear
signific
risk
bacteremia
consequ
pulmonari
gastrointestin
respect
viral
infect
notabl
patient
good
syndrom
high
rate
cmv
infect
note
quit
sever
includ
fatal
case
cmv
multipl
report
infect
parasit
giardia
common
fungal
infect
candid
addit
previous
mention
cmv
candida
opportunist
infect
may
encount
patient
good
syndrom
includ
pjp
recurr
herp
simplex
viru
hsv
human
herpesviru
result
kaposi
patient
thymoma
patient
good
syndrom
high
rate
autoimmun
pure
rbc
aplasia
myasthenia
gravi
oral
lichen
planu
inflammatori
inflammatori
coliti
report
case
although
mechan
underli
develop
patient
remain
poorli
dysregul
function
impair
regulatori
subset
particular
may
predispos
autoimmun
inflammatori
complic
patient
remain
demonstr
cornerston
manag
good
syndrom
includ
thymectomi
ig
although
thymectomi
associ
resolut
autoimmun
benefit
observ
regard
patient
immun
function
may
role
prophylact
antibiot
select
patient
guidelin
treatment
decis
typic
made
individu
patient
recurr
bacteri
infect
acid
fluoroquinolon
may
reason
choic
prophylaxi
tabl
acyclovir
use
patient
recurr
hsv
vzv
valganciclovir
use
case
cmv
patient
recurr
candidiasi
may
benefit
prophylact
fluconazol
altern
set
fluconazol
resist
pjp
prophylaxi
indic
patient
lymphopenia
toxoplasma
seroposit
syndrom
character
eczematoid
dermat
recurr
pulmonari
skin
infect
elev
total
ige
major
underli
mechan
respons
multisystem
diseas
mutat
signal
transduc
activ
transcript
patient
present
infanc
eczematoid
pustular
rash
wound
cultur
often
grow
staphylococcu
aureu
patient
often
develop
recurr
pneumonia
secondari
aureu
h
influenza
fact
patient
histori
recurr
pneumonia
multicent
pneumatocel
bronchiectasi
develop
spectrum
pulmonari
infect
may
chang
may
includ
p
aeruginosa
nontubercul
mycobacteria
filament
mold
aspergillu
patient
must
treat
prophylact
antibiot
p
aeruginosa
aureu
well
prophylact
antifung
therapi
life
choic
antifung
therapi
depend
specif
fungal
pathogen
presenc
cystic
lung
diseas
tabl
play
import
role
function
via
follicular
helper
provid
rational
use
ig
replac
patient
hie
fact
patient
ig
replac
therapi
shown
possibl
reduc
incid
identif
molecular
defect
mani
patient
variant
dedic
cytokinesi
gene
categor
note
mani
famili
member
activ
botulinum
toxin
substrat
rac
famili
member
initi
actin
reorgan
play
crucial
role
mani
immun
process
patient
defici
present
sever
viral
skin
infect
wart
molluscum
contagiosum
sever
atop
diseas
food
allergi
eczema
recurr
aureu
skin
infect
patient
may
also
increas
risk
malign
particular
lymphoma
squamou
cell
key
laboratori
find
includ
decreas
number
b
cell
elev
ige
level
eosinophilia
main
treatment
patient
defici
undergo
stem
cell
transplant
patient
defici
treat
ig
replac
therapi
well
prophylact
decreas
risk
lung
skin
infect
primari
immunodefici
treatment
consortium
propos
formal
diagnost
criteria
scid
typic
classic
scid
character
profound
lymphopenia
count
togeth
phytohemagglutinin
pha
respons
compar
control
valu
identif
matern
cell
infant
partial
leaki
scid
includ
omenn
syndrom
diagnos
base
lymphopenia
adjust
age
age
year
age
year
age
year
pha
respons
control
although
b
cell
present
mani
type
scid
common
gamma
chain
defici
defici
antibodi
product
greatli
impair
absenc
adequ
costimul
cell
patient
scid
often
present
chronic
respiratori
infect
protract
diarrhea
chronic
candidiasi
common
pathogen
includ
bacteria
salmonella
pseudomona
virus
parainfluenza
respiratori
syncyti
viru
adenoviru
cmv
protozoa
fungi
pjp
candida
patient
scid
must
treat
prophylaxi
pjp
well
ig
replac
therapi
shown
reduc
risk
infect
definit
treatment
even
follow
success
hsct
mani
patient
engraft
inde
half
survivor
shown
requir
ig
replac
therapi
includ
patient
patient
recombin
activ
gene
defici
pid
diseas
specif
primari
antibodi
defici
repres
heterogen
group
disord
patient
immun
disord
vulner
wide
varieti
infect
although
specif
pid
diseas
appear
signatur
regard
confer
risk
certain
infect
thorough
understand
predisposit
observ
diagnos
allow
clinician
anticip
infecti
complic
make
full
use
armamentarium
includ
ig
replac
therapi
prophylact
antibiot
even
hsct
certain
instanc
reduc
morbid
mortal
highli
vulner
patient
author
disclos
conflict
interest
